Medovate has announced that it has entered into an agreement with Mercury Medical for exclusive distribution of the FDA-cleared device SAFIRA (SAFer Injection for Regional Anesthesia) across the whole of the US.
The agreement also includes the newly launched SAFIRA Palm Operator which has been launched in the US market to offer anesthesiologists more versatility and choice when using the SAFIRA regional anesthesia system.
In California Mercury Medical will also be distributing the SAFIRA NRFit syringe, which provides an alternative to the Luer connection syringes with which the SAFIRA system was originally introduced, further enhancing the system’s revolutionary benefits for patient safety.
Stuart Thomson, managing director of Medovate, said: “As our company grows, it has been our vision to centralise our US distribution with a primary distributor to streamline processes and provide a single contact point for clinicians in the US interested in SAFIRA. Mercury Medical have positioned themselves as a US leader in providing technological advances for clinicians in both airway solutions and anesthesia – a philosophy that aligns very well with Medovate and SAFIRA. We are excited to this partnership with them as primary distributor of our SAFIRA system in the US and look forward to entering this next phase of our journey.”
Developed with clinicians working in the UK’s NHS to promote safer injection during single shot regional anesthesia peripheral nerve block procedures, the SAFIRA system transforms regional anesthesia into a one-person procedure, giving the anesthesiologist full control of the injection at all times. It also includes a built-in safety mechanism to automatically limit injection pressure helping to reduce the risks of nerve damage, promoting patient safety.
